Takeda Pharmaceutical Files 6-K Report
Ticker: TKPHF · Form: 6-K · Filed: Jun 10, 2024 · CIK: 1395064
| Field | Detail |
|---|---|
| Company | Takeda Pharmaceutical Co Ltd (TKPHF) |
| Form Type | 6-K |
| Filed Date | Jun 10, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: foreign-private-issuer, regulatory-filing
TL;DR
Takeda filed a 6-K on 6/10/24, standard foreign issuer report.
AI Summary
Takeda Pharmaceutical Company Limited filed a Form 6-K on June 10, 2024, reporting as a foreign private issuer. The filing indicates Takeda's principal executive offices are located at 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, Japan.
Why It Matters
This filing is a routine report for foreign private issuers, providing an update on Takeda's corporate information and regulatory compliance.
Risk Assessment
Risk Level: low — This is a routine administrative filing and does not contain new financial or operational information that would typically impact risk.
Key Players & Entities
- TAKEDA PHARMACEUTICAL CO LTD (company) — Filer
- 0001395064-24-000066 (filing_id) — Accession Number
- 001-38757 (company_id) — SEC File Number
- June 10, 2024 (date) — Filing Date
FAQ
What type of filing is this Form 6-K?
This Form 6-K is a Report of Foreign Private Issuer pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934.
Who is the filer of this report?
The filer is TAKEDA PHARMACEUTICAL CO LTD.
What is Takeda Pharmaceutical's principal executive office address?
Takeda Pharmaceutical's principal executive offices are located at 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, 103-8668 Japan.
Does Takeda file an annual report under Form 20-F or 40-F?
Takeda indicates it files its annual reports under cover of Form 20-F.
When was this Form 6-K filed?
This Form 6-K was filed on June 10, 2024.
Filing Stats: 392 words · 2 min read · ~1 pages · Grade level 16.5 · Accepted 2024-06-10 06:10:42
Filing Documents
- form6k_061024.htm (6-K) — 22KB
- 0001395064-24-000066.txt ( ) — 23KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. TAKEDA PHARMACEUTICAL COMPANY LIMITED Date June 10, 2024 By s Norimasa Takeda Norimasa Takeda Chief Accounting Officer and Corporate Controller June 10, 2024 Dear Shareholders Christophe Weber President and Representative Director Takeda Pharmaceutical Company Limited 1-1, Doshomachi 4-chome Chuo-ku, Osaka Partial Correction to the Notice of Convocation of the 148th Ordinary General Meeting of Shareholders Takeda Pharmaceutical Company Limited (the "Company") hereby reports that there is a part to be corrected in the Notice of Convocation of the 148th Ordinary General Meeting of Shareholders (the "Notice") and that the Company therefore decided to make corrections to the said part as described herein below. 1. Correction part The numbers of Company ADS to be provided to Mr. Christophe Weber and Dr. Andrew Plump, which are described in the Second Proposal (pages 8 and 9) in the "Reference Document for the General Meeting of Shareholders" of the Notice 2. Contents of the correction (Underlined sections indicate changes) Mr. Christophe Weber Before correction Number of Company ADS to be provided 211,756 shares After correction Number of Company ADS to be provided 211,810 shares Dr. Andrew Plump Before correction Number of Company ADS to be provided 739,162 shares After correction Number of Company ADS to be provided 739,658 shares End of document